ArticleCancer control : journal of the Moffitt Cancer Center
Efficacy and Safety of Vascular-Targeting Agents Plus Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients: A Multicenter Clinical Cohort Study.
Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionPlatinum-based chemotherapy is important for the treatment for recurrent or metastatic nasopharyngeal carcinomas (RM-NPCs), as recommended by current clinical guidelines. However, the prognosis of RM-NPC patients remains poor. This study aimed to evaluate the efficacy and safety of vascular-targeting agents apatinib or anlotinib plus chemotherapy for RM-NPC treatment.MethodsThis retrospective multicenter study, conducted at 4 hospitals in Guangxi Province, China, between January 2017 and December 2021, included 198 patients. Propensity score matching (PSM) was used to minimize potential selection bias between groups. After PSM, a total of 150 patients were included in the study. Chemotherapy was administered with and without vascular-targeting agents in 58 and 92 patients, respectively. The primary endpoint was progression-free survival (PFS), assessed by a blinded independent review committee according to RECIST v.1.1. The secondary end points were overall survival (OS) and safety.ResultsAfter PSM, median PFS was significantly higher in the combination group (8.0 months [95% CI, 5.7-8.3 months]) than in the chemotherapy alone group (5.0 months [95% CI, 4.1-5.9 months],
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.